On February 5, Array BioPharma has reported a stronger quarterly result for the company’s commercialized drug, BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib). Moreover, the Array’s FDA granted candidate, Beacon CRC, in the new data from Phase III study showed an overall response rate of 48% and updated median progression-free-survival of eight months. In addition, when the large pharma company Eli Lilly (LLY) acquired Loxo Oncology (LOXO) for $8 billion, a number of cancer developing companies has faced with buying spike, Array BioPharma (ARRY) added up 13.3% in that day.
Array